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a  b  s  t  r  a  c  t
Glucagon-like  peptide  1  (GLP-1),  produced  in the  intestine  and  hindbrain,  is known  for  its glucoregula-
tory  and  appetite  suppressing  effects.  GLP-1  agonists  are  in  clinical  use for treatment  of type  2 diabetes
and  obesity.  GLP-1,  however,  may  also  affect  brain  areas  associated  with  emotionality  regulation.  Here
we aimed  to characterize  acute  and  chronic  impact  of  GLP-1  on anxiety  and  depression-like  behavior.
Rats  were  subjected  to  anxiety  and  depression  behavior  tests  following  acute  or chronic  intracerebroven-
tricular  or  intra-dorsal  raphe  (DR) application  of  GLP-1  receptor  agonists.  Serotonin  or serotonin-related
genes  were  also  measured  in the  amygdala,  DR  and  the  hippocampus.  We  demonstrate  that  both  GLP-1
and  its long  lasting  analog,  Exendin-4,  induce  anxiety-like  behavior  in  three  rodent  tests  of this  behavior:
black  and  white  box,  elevated  plus  maze  and  open  ﬁeld  test  when  acutely  administered  intraperitoneally,
into  the  lateral  ventricle,  or directly  into  the  DR. Acute  central  GLP-1  receptor  stimulation  also  altered
serotonin  signaling  in  the  amygdala.  In contrast,  chronic  central  administration  of Exendin-4  did  not  alter
anxiety-like  behavior  but  signiﬁcantly  reduced  depression-like  behavior  in  the  forced  swim  test.  Impor-
tantly, this  positive  effect  of Exendin-4  was not  due  to signiﬁcant  body  weight  loss  and  reduced  food
intake,  since  rats  pair-fed  to Exendin-4  rats  did  not  show  altered  mood.  Collectively  we show  a  striking
impact  of  central  GLP-1  on emotionality  and  the  amygdala  serotonin  signaling  that  is  divergent  under
acute  versus  chronic  GLP-1  activation  conditions.  We  also  ﬁnd  a  novel  role  for the  DR  GLP-1  receptors  in
regulation  of behavior.  These  results  may  have  direct  relevance  to  the  clinic,  and indicate  that  Exendin-4
may  be  especially  useful  for  obese  patients  manifesting  with  comorbid  depression.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Obesity is a major global health concern and signiﬁcant efforts
re now underway to ﬁnd an effective pharmacotherapy to aid
eight-reduction and metabolic health improvement. Since body
eight and food intake are under the tight control of the central
ervous system (CNS) (Berthoud, 2002) it is likely that effective
nti-obesity therapeutics will target the CNS. With targeting the
NS, potential psychiatric side effects of any treatment should
e closely examined, especially since many of the substances
nown to control body weight have also been shown to impact
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nd  Physiology, The Sahlgrenska Academy at the University of Gothenburg, Medic-
naregatan 11, P.O. Box 434, SE-405 30 Gothenburg, Sweden. Fax: +46 31 786 3512.
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ttp://dx.doi.org/10.1016/j.psyneuen.2015.11.021
306-4530/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
mood and emotionality. Recently withdrawn anti-obesity treat-
ment, rimonabant, was  revealed to induce signiﬁcant psychiatric
side effects, namely anxiety and depression, after the drug was
already approved (Moreira et al., 2009). Animal models conﬁrm
this negative impact on mood (Navarro et al., 1997). Therefore, a
very careful investigation of mood impact of any potential new
treatment is warranted.
GLP-1 is well recognized for its role in energy balance regula-
tion (Holst, 2007). It is produced in the intestinal L-cells and also
in neurons primarily in the nucleus of the solitary tract (NTS) of
the hindbrain (Merchenthaler et al., 1999). In addition microglia
have recently been indicated as a potential CNS source of GLP-
1 secretion (Kappe et al., 2012). Plasma GLP-1 levels, and also
the activity of GLP-1 producing neurons increase in response to
a meal (Parker et al., 2010). Analogs of GLP-1, including Exendin-4
(EX4), are approved for clinical use in patients with type 2 dia-
betes due to their glucoregulatory effects, effects thought to be
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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rimarily mediated by peripheral GLP-1 receptors (GLP-1R). GLP-
R activation also reduces food intake and body weight, effects
argely mediated by the central GLP-1R (Trapp and Richards, 2013;
urton et al., 1996). Another GLP-1 analog, liraglutide, was just
ecently approved by the FDA for use in clinical populations of
bese patients due to its weight-loss effect. Importantly, GLP-1
nalogs were clearly shown to rapidly cross the blood brain bar-
ier (Kastin and Akerstrom, 2003). GLP-1 is postprandially secreted
ith another peptide, glucagon-like peptide-2 (GLP-2) which has
een shown to have similar effects on food intake in addition to
ffects in the gastrointestinal tract (Brubaker et al., 1997; Thulesen,
004). Moreover GLP-2 receptors are expressed in many areas
ssociated with depression such as the hippocampus and cerebral
ortex, and has previously been shown to display anti-depressant
ike effects (Iwai et al., 2009; Lovshin et al., 2004; Nelson et al., 2007;
ang-Christensen et al., 2000). However, much less in known about
ts role in anxiety-like behavior.
GLP-1Rs are also found in areas not classically associated with
nergy balance regulation but rather regulation of mood and emo-
ionality including the amygdala, the dorsal raphe (DR) and the
ippocampus (Merchenthaler et al., 1999). The role of GLP-1R in
he DR is entirely unexplored. Furthermore, little is known about
he effects of GLP-1 on mood, and the few studies that are avail-
ble produced conﬂicting results. Some preclinical studies found
hat CNS-directed GLP-1 injections in rodents may  increase anxi-
ty (Gulec et al., 2010; Kinzig et al., 2003), others show no changes
n anxiety-like behavior (Krass et al., 2012, 2015), and recent
tudies even found an anxiolytic effect (Sharma et al., 2015a,b,c;
omsuoglu Celikyurt et al., 2014). While in one clinical study no
nxiogenic properties were observed after intravenous adminis-
ration of GLP-1 (Strawn et al., 2008). Another study in diabetic
atients, receiving continuous 6-month treatment with a GLP-1
nalog, did not ﬁnd elevated anxiety and depression scores in qual-
ty of life tests, on the contrary scores were signiﬁcantly reduced
nd the well-being scores were superior to those of the control
roup (Grant et al., 2011). Nonetheless studies on diabetic patients,
hile clinically relevant, make it difﬁcult to decouple the potential
eneﬁcial effect of the treatment on mood from mood improve-
ent associated with improvement of diabetic symptoms. Thus,
urther studies are still needed to understand the conﬂicting results
f GLP-1 treatment on mood.
Here we aimed to understand both acute and chronic impact
f central GLP-1 and its clinically utilized analog, EX4, on anxiety
nd depression-like behaviors. We  used several complementary rat
odels of anxiety-like behavior: the elevated plus maze (EPM), the
pen ﬁeld, and the black and white chamber test in combination
ith central and intraparenchymal DR-directed GLP-1 microinjec-
ions. We further evaluated whether both acute and chronic GLP-1
lters depression—like behavior in a forced swim test (FST) (Porsolt
t al., 1977). Lastly, because of the important role of serotonin
n mood, along with the pattern of results obtained with GLP-1
eminiscent of the effect seen with selective serotonin reuptake
nhibitors (SSRIs), we evaluated the impact of central GLP-1R acti-
ation on serotonin turnover and expression of serotonin-related
enes in key emotionality brain regions: the amygdala, the DR and
he hippocampus.
. Materials and methods
.1. AnimalsAdult male Sprague-Dawley rats, weighing 200–250 g (Charles
iver, Germany) were housed in individual plastic cages under
2/12 h dark/light cycle, at 20 ◦C and 50% humidity. Standard chow
Harlan Tekland; Norfolk, England) and water were available addocrinology 65 (2016) 54–66 55
libitum unless otherwise indicated. The University of Gothenburg
Institutional Animal Care and Use Committee guidelines approved
all experiments (ethical permission 195-13).
2.2. Drugs
GLP-1 (7-36), Exendin-4 (EX4; GLP-1R agonist), GLP-2 and
Angiotensin II were purchased from Tocris (Bristol, UK). All sub-
stances were dissolved in artiﬁcial cerebrospinal ﬂuid (aCSF),
vehicle for central injections, and stored as aliquots in −20 ◦C.
2.3. Brain cannulation
For behavioral testing, all rats were implanted with a guide
cannula (26 gauge cannula; Plastics One, Roanoke, VA) allowing
brain drug injections targeting the lateral ventricle (LV) or DR
under ketamine/xylazine anesthesia. The cannulas were positioned
and attached to the skull with dental acrylic and jeweler’s screws
and closed with an obturator (Dickson et al., 2012). The following
coordinates were used for the LV: ±1.6 from the midline, 0.9 mm
posterior to bregma, and 2.0 mm ventral to skull, with injector
aimed 4.0 mm ventral to the skull; and for the DR guide cannula:
7.7 mm posterior to bregma, and 4.8 mm ventral from the surface
of the skull, with injector aimed 6.8 mm ventral to skull. The LV
placement was  veriﬁed with the angiotensin II drinking test. Brieﬂy,
angiotensin II was injected at a dose of 20 ng in 2 l of aCSF and
water intake was  measured immediately. Rats that drank at least
5 ml  of water in 30 min  were considered to have a correct cannula
placement. The microinjection site for the DR guide cannula was
veriﬁed post mortem by microinjection of India ink at the same
microinjection volume (0.3 l) used throughout the study.
2.4. Behavioral testing
Three complementary tests were used to examine anxiety-like
behavior. Although all three tests represent approach–avoidance
anxiety testing procedures, it is important to emphasize that the
pharmacology and the neurobiology behind the response in each
test may  differ, thus the use of this battery-style approach for
assessing novel pharmacological agents is proposed to offer more
accurate conclusions on their anxiety impact. All behavioral tests
were carried out during the light cycle, avoiding only the two hours
after the lights were turned on and the two-hour period preceding
the dark onset. All tissue collection was  performed during the same
hours of the light cycle as behavioral testing.
2.5. Elevated plus maze (EPM)
The EPM, originally described by Pellow and colleagues (Pellow
et al., 1985), is a well-established rodent test used to characterize
anxiety-like behavior. The open arms of the maze provide an anxio-
genic environment, and less time spent exploring the open arms is
indicative of higher levels of anxiety-like behavior. The EPM appa-
ratus (Med-Associates, Georgia, VT, USA) was  made of black acrylic
plastic and consisted of two open arms, 10 × 50 cm,  and two closed
arms 10 × 50 × 40 cm and a central square platform. Each rat was
placed on the central platform and allowed to move freely for 5 min.
The amount of time spent on each arm was detected by measur-
ing beam breaks of infrared lasers located at the beginning of each
arm and recorded with MED-SYST-8A PCI operating and software
package, provided by Med-Associates. The EPM was cleaned with
a damp tissue after each rat. All behavioral tests were carried out
during the light cycle as described above; this was  done to mini-
mize the potential hunger-suppressing effect of GLP-1R (ad libitum
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ed rats eat little during the light cycle, thus both treatment rats and
ontrol rats should have low levels of hunger).
.6. Open ﬁeld test
Rats were placed in a brightly lit arena (68 × 68 × 35 cm,  Kungs-
acka mät-och reglerteknik AB, Fjärås, Sweden or 43 × 43 × 31 cm,
ed-Associates, Georgia, VT, USA) and allowed to freely explore
or 60 min  during the open ﬁeld test. The open ﬁeld chambers were
quipped with a grid of photocells for detecting movement. Photo-
ells were coupled to a computer-based system that registers the
nimals’ movements in the box (Ericson et al., 1991) or time spent in
he center or periphery of the box. The brightly lit exposed arena is
 highly anxiogenic environment and anxiety levels were assessed
y the amount of activity of the rat in the more anxiety-provoking
entral compartment.
.7. Black and white test
The boxes (Med-Associates, Georgia, VT, USA) consisted of two
onnected compartments with distinct visual qualities, a dark side
0 lux) and a light side with a light source (174 lux). The key measure
n this test is a change in willingness of a subject to explore the light
ide during a 30 min  test session. The light compartment is believed
o be more aversive to the rat than the dark compartment (Crawley,
981). Anxiolytic drug administration increases the amount of time
pent in the light compartment.
.8. Forced swim test (FST)
The FST was originally developed by Porsolt and colleagues
Porsolt et al., 1977) to screen for anti-depressive effect of phar-
acotherapeutics. Here we used the modiﬁed version of the FST
hown to provide a greater reliability for detection of depressant
r antidepressant-like effects for compounds that affect the sero-
onergic system (Slattery and Cryan, 2012). Brieﬂy all rats were
llowed to swim individually in an acrylic cylinder (height: 58 cm,
iameter: 21 cm)  ﬁlled with fresh water before each trial (25 ◦C and
0 cm deep). A 15 min  pre-swim was performed 24 h prior to test
ession. On the test day, animals were treated with either vehicle
r drug and allowed to swim for a period of 5 min; the amount
f time the rats spent ﬂoating (immobility), actively swimming or
limbing was recorded with a video camera and later scored by an
xperimenter blinded to the treatment conditions. Immobility was
eﬁned as an absence of any movement other than those necessary
o keep the head and nose above the surface of the water and was
onsidered an index of depressive behavior.
.8.1. PICA test
To determine whether anxiety response to GLP-1R activa-
ion is associated with nausea, the PICA response was  measured
consumption of non-nutritive substances that mimics emesis in
pecies not capable of the emetic response). Rats were allowed to
ample kaolin for at least 3 days before the Ex4 or GLP-1 injection to
void association of kaolin with injections. Kaolin intake was  mea-
ured at 1 and 24 h after injection. The doses of Ex4 (0.05 g) and
LP-1 (2 g) were chosen based on their earlier shown ability to
nduce anxiety-like behavior when injected into the DR.
.9. RNA isolation and mRNA expressionDR and amygdala gene expression levels were measured after
cute or chronic (daily, for 10 days) LV injection of EX4 (0.2 g)
r vehicle (aCSF). The following serotonin production, receptor,
egradation or uptake-related genes were examined: Tph2, Htr1a,docrinology 65 (2016) 54–66
Htr2a, Htr2c, Htr3a, Htr5a, Maob and SERT. These genes were cho-
sen based on their previously shown importance for anxiety or
depression-like behaviors as discussed in detail in the discussion
section. Ninety minutes after EX4 or aCSF injection (for the acute
study) or after the last behavioral test of the chronic study the brains
were rapidly removed and DR or amygdala was dissected using a
brain matrix based on the areas position in a rat brain atlas. The tis-
sues were then frozen in liquid nitrogen and stored at −80 ◦C. Gene
expression was  determined using TaqMan RT-PCR. For details see
supplementary information.
2.10. Serotonin turnover
For the acute effect of EX4 on serotonin turnover thirty minutes
after the LV injection of EX4 or vehicle, rats were lightly sedated
using isoﬂurane and decapitated. For chronic effect of EX4 the
brains were dissected 24 h after the last EX4 injection. Brains were
rapidly removed and the amygdala or the hippocampus was dis-
sected using a brain matrix. Dissected tissue was  frozen on dry ice
and stored in −80 ◦C. Tissue concentrations of serotonin and its
metabolite (5-HIAA) were determined via high performance liquid
chromatography (Hansson et al., 2014). For details see supplemen-
tary information.
3. Experimental design
3.1. Effect of acute intraperitoneal, central or intra-DR GLP-1, EX4
and GLP-2 administration on anxiety-like behavior
To assess the impact of peripheral acute EX4 injection (clinically
relevant compound and clinically relevant route of application) on
anxiety-like behavior two doses of EX4 (0.1 or 1.0 g/kg) or saline
were injected intraperitoneally. The EPM and the open ﬁeld testing
were performed 20 or 25 min  after EX4 injection, respectively. To
assess the impact of central GLP-1, EX4 and GLP-2 on anxiety-like
behavior, separate groups of rats received LV injections of GLP-
1 (10 g), EX4 (0.15 g), GLP-2 (10 g) or vehicle (1 l of aCSF).
Injections were delivered 20 min  prior to each anxiety test. Doses
were chosen based on their previously reported effectiveness in
reduction of food intake or food reward (Dickson et al., 2012; Tang-
Christensen et al., 2000; Turton et al., 1996). To assess the impact of
GLP-1, EX4 and GLP-2 in the DR on anxiety-like behavior, separate
groups of rats received DR-directed microinjections of GLP-1 (2 g),
EX4 (0.05 g), GLP-2 (2 g) or 0.3 l of aCSF 20 min  prior to each
anxiety test. These doses were chosen to be below LV threshold for
effect to avoid potential confounding effect of potential drug leak-
age into the cerebral aqueduct located just above the DR. For this,
and below described designs, all rats were naive to the tests per-
formed except for the intraperitoneal injection experiment, which
utilized a counterbalanced (Latin square) design (all rats received
each drug condition separated by at least 48 h). To make sure that
the repeated exposure to the EPM or the open ﬁeld test did not
change behavior during the test, we assessed the effect of multiple
exposure to the test statistically, by comparing the performance
of vehicle-injected rats on each test day, and did not ﬁnd any sig-
niﬁcant effect of exposure # for either EPM or open ﬁeld (ANOVA
on amount of time spent in the center of open ﬁeld, F(2,13) = 1.01,
p = 0.39; EPM open arm time: F(2,13) = 0.47, p = 0.64). During the EPM
test six rats were taken out from the central experiment and ﬁve
rats from the IP experiment due to open arm entry sensor malfunc-
tion (no data recorded).3.2. Anti-depressive effect of acute central GLP-1R activation
To assess the effect of GLP-1R stimulation on depression-like
behavior, EX4 (0.2 g) or vehicle (1 l) was injected into the LV.
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ffects of acute treatment were evaluated after one single injection
f EX4. The FST test was performed for each rat individually 1 h
fter drug administration.
.3. Impact of chronic central GLP-1R activation on anxiety and
epression-like behavior
Rats were injected with EX4 (0.2 g) or vehicle (1 l of aCSF)
nce a day, intra-LV (for a total of 9 days of injections). A third group
f rats was included in order to determine whether the emotional-
ty effect of chronic GLP-1R activation, previously shown to reduce
ood intake and body weight, was not simply due to body weight or
ody fat loss. These rats were pair-fed daily to the amount of chow
aten by the EX4-treated rats. The body weight and food intake of
ach rat was measured daily. The FST was performed on day 9 of
njections and the EPM was performed on day 10. Both tests were
erformed during the light cycle 24 h after the last central injec-
ion to separate the chronic and acute effect of the treatment. One
at was excluded from the chronic treatment FST test since he was
aken out of the water before completion of the test.
.4. Statistics
All statistical analysis was performed in Graph Pad Prism soft-
are (GraphPad Software, Inc., GraphPad, San Diego, CA). Statistical
igniﬁcance was analyzed using Student’s t test or ANOVA followed
y Holm–Sidak’s multiple comparison test. Kruskal–Wallis test was
sed when unequal variances were discovered. All data are pre-
ented as mean ± standard error of the mean (de Morentin et al.,
014).
. Results
.1. Acute peripheral administration of EX4 increases anxiety-like
ehavior
Acute intraperitoneal injection of EX4 dose-dependently
ncreased anxiety-like behavior in EPM test as suggested by the
educed % time spent in the open arm of the maze produced by
he 1 g/kg dose of EX4 (Fig. 1A ; repeated measures ANOVA;
(2,20) = 4.31, p < 0.05) and reduced number of entries to the open
rms (Fig. 1B; repeated measures ANOVA; F(2,20) = 4.93, p < 0.05).
X4 at the 1 g/kg dose also potently reduced the amount of time
pent in the center of the open ﬁeld arena (Fig. 1C; repeated mea-
ures ANOVA; F(2,30) = 9.25, p < 0.001).
.2. Acute central administration of GLP-1 and EX4 increases
nxiety-like behavior
Acute LV injection of either one of the GLP-1R agonists, GLP-
 or EX4, increased anxiety-like behavior in the black and white
est, during which the rats injected with the GLP-1 agonists chose
o spend signiﬁcantly less time in the bright compartment (Fig. 2A
 ANOVA; F(2,26) = 5.95, p < 0.01) of the black and white box with-
ut altering (ANOVA; F(2,26) = 0.95, p = 0.4) overall physical activity
Fig. 2B). Elevated plus maze data indicate a similar trend for
ncreased anxiety after central EX4 treatment, however due to
igh variability the results do not reach statistical signiﬁcance;
ruskal–Wallis test due to unequal variances (p = 0.27 for % time
n open arm; Fig. 2C, and p = 0.14 for% open arm entries; Fig. 2D).
ince the amount of time spent in the open arms of the EPM was
elatively low for the vehicle-treated rats it is possible the effect
ize of EX4 may  have been larger or more consistent if the baseline
as higher. However in the experiment where rats were peripher-
lly injected with EX4 the amount of time spent in the open arm
as nearly ﬁve times higher by the vehicle-treated rats, yet thedocrinology 65 (2016) 54–66 57
effect size of EX4 in this test was also very small (albeit signiﬁ-
cant). GLP-1 signiﬁcantly reduced activity in the center of the open
ﬁeld arena, a behavior associated with increased anxiety in rodents
(Fig. 2E) without changing the activity in the periphery of the arena
(Fig. 2F). EX4 also signiﬁcantly reduced activity in the center of the
open ﬁeld arena (F(2,20) = 3.58, p < 0.05), a behavior associated with
increased anxiety in rodents (Fig. 2G) but also changed the activity
in the periphery of the arena (F(2,20) = 5.04, p < 0.05; Fig. 2H).
4.3. The effect of acute central GLP-1R activation on
depression-like behavior
No statistically signiﬁcant differences were found between rats
acutely treated with EX4, or GLP-1 and vehicle treated rats on the
amount of time spent swimming, ﬂoating or climbing during the
FST test (Fig. 3).
4.4. Impact of acute central GLP-1R stimulation on serotonin
turnover and serotonin receptor expression
The serotonin turnover, calculated as a ratio of 5-HIAA to sero-
tonin was  signiﬁcantly increased by acute central EX4 treatment
in the amygdala (Fig. 4A) but not the hippocampus (Fig. 4B). These
data suggest an impact of central GLP-1R activation on serotonin
signaling in the amygdala. Central injection of EX4 also signiﬁ-
cantly increased the mRNA expression of two serotonin receptors,
5-HTR2A and 5-HTR2C, in the amygdala (Fig. 4C) but did not alter
gene expression for Tph2, 5HT1A and SERT in the DR (Fig. 4D).
4.5. Acute DR administration of GLP-1 and EX4 on anxiety-like
behavior
Based on the observed impact of GLP-1R activation on seroto-
nergic turnover, we hypothesized that GLP-1 may be exerting its
anxiogenic effects by acting directly on the DR nucleus. To test
this, rats were microinjected with GLP-1, EX4 or aCSF directly into
the DR. Similar to the results obtained with the LV injection, rats
injected with GLP-1 or EX4 into the DR spent signiﬁcantly less
time in the white chamber of the black and white box (ANOVA;
F(2,33) = 7.44, p < 0.005) without altering their general motor activ-
ity (F(2,33) = 1.39, p = 0.26) compared to the vehicle treated group
(Fig. 5A and B). Rats microinjected with EX4 or GLP-1 into the
DR also spent three times less time in the open arms of the
maze (ANOVA; F(2,23) = 4.00, p < 0.05) compared to vehicle treated
controls (Fig. 5C), they were also less likely to enter the open
arm (ANOVA; F(2,23) = 3.61, p < 0.05) (Fig. 5D). However they did
not display signs of malaise as measured by the PICA response
(F(2,32) = 0.51, p = 0.6 and F(2,32) = 0.44, p = 0.6 for 1 and 24 h respec-
tively) (Fig. 5E). PICA test outcome, together with the lack of effect
on general motor activity of these treatments, strongly suggest
a lack of illness or malaise coupled to the anxiety-like behavior
induced by DR-targeted GLP-1R activation.
4.6. Acute LV and DR GLP-2 administration impact on anxiety
GLP-2 reduced anxiety-like behavior in the open ﬁeld test, as
demonstrated by increased activity in the center of the open ﬁeld
arena after LV treatment (Fig. S1A). However GLP-2 produced no
changes in anxiety-like behavior in the EPM or black and white
test (Fig. S1C–E). Microinjection of GLP-2 into the DR did not sig-
niﬁcantly change anxiety-like behavior, measured by the EPM test
(Fig. S1F).
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Fig. 1. Peripheral acute injection of GLP-1 analogue, EX4, increases anxiety-like behavior. EX4 reduced the amount of time spent in the open arm of the elevated plus maze
(A)  and reduced the % of open arm entries, n = 11 (B). Peripheral EX4 also potently reduced the amount of time spent in the central region of the open ﬁeld, n = 16 (C). Data
are  expressed as mean ±SEM. *p < 0.05, ***p < 0.0005.
Fig. 2. Central acute GLP-1R activation increases anxiety-like behavior. GLP-1 or EX4 potently reduce the amount of time spent in the white chamber of the black and white
box  (A) without altering overall physical activity (B). n = 7–14 per each treatment group. Elevated plus maze data indicate a similar trend for increased anxiety after central
EX4  treatment, however due to high variability the results do not reach statistical signiﬁcance;% time in open arm (C) and % open arm entries (D). n = 5–11 per each treatment
group.  Central GLP-1 injections also reduced activity in the central region of the open ﬁeld (E, p < 0.05), without changing the activity in the peripheral region (F). n = 11–14.
EX4  also signiﬁcantly reduced activity in the center of the open ﬁeld arena, a behavior associated with increased anxiety in rodents (Fig. 2G) but also changed the activity in
the  periphery of the arena (Fig. 2H). n = 3–14. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.005.
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Fig. 3. Acute GLP-1R activation does not change depression-like behavior. No statistically
and  vehicle treated rats on the amount of time spent swimming (A), ﬂoating (B) or climb
per  each treatment group.
Fig. 4. Acute GLP-1R activation alters serotonin turnover and serotonin receptor
expression in the amygdala. Acute injections of EX4 into the lateral ventricle increase
5-HIAA/5-HT turnover in the amygdala (A) but not the hippocampus (B). This treat-
ment also increases the expression of amygdala serotonin receptors previously
associated with anxiety behavior control: 5HT2A and 5HT2C (C). On the other hand
the same treatment does not change the expression of serotonin neuron autorecep-
tors or serotonin synthesizing enzyme in the dorsal raphe (D). Data are expressed
as  mean ± SEM. n = 7-8 per each treatment group. *p < 0.05. signiﬁcant differences were found between rats acutely treated with EX4, or GLP-1
ing (C) during the forced swim test. Data are expressed as mean ± SEM. n = 12–21
4.7. Chronic central GLP-1R activation reduces depression-like
behavior without affecting anxiety
In contrast to the acute effects of EX4, rats chronically treated
with EX4 displayed reduced depression-like behavior as evidenced
by a reduced amount of time spent on the passive behavior (immo-
bility) (F(2,32) = 5.487, p < 0.01; Fig. 6B) and increased active behavior
(Swimming) (ANOVA; F(2,32) = 9.244, p < 0.001; Fig. 6A) during the
FST. Since the amount of time spent on passive behavior was  rela-
tively low in the vehicle-treated group it is possible that the effect
size of EX4 may  have been larger in rats displaying higher amount
of passive behavior. In the chronic treatment experiment an addi-
tional group of rats was tested, a group that had their body weight
matched to that of the EX4-treated rats in order to discern whether
the positive effect of EX4 on mood was  connected to the body
weight loss and reduced food intake displayed by the EX4-treated
rats. Food was given once daily to pair-fed subjects. Importantly,
body weight loss, matched to the loss measured in EX4-treated
rats, did not change FST behavior leading to the conclusion that
the positive effects of EX4 on mood in the FST were not due to the
weight-loss effects of EX4. Anxiety-like behavior, measured in the
EPM test, was not altered by chronic treatment with EX4 (Fig. 6D
and E). Thus, chronic injections of EX4 were neither anxiogenic nor
anxiolytic.
As expected based on the well known weight-reducing effect
of the central GLP-1R activation, rats chronically treated with
EX4 signiﬁcantly reduced their body weight (Fig. 6F). Two-way
repeated measures ANOVA indicated a signiﬁcant effect of treat-
ment (F(8,256) = 6.017, p < 0.001) and day (F(2,32) = 8.437, p < 0.0001).
The reduction in body weight was consistent with reduced
chow intake (compared to the vehicle-treated rats) (F(2,32) = 5.49,
p < 0.001; Fig. 6G). After two days the animals stopped losing addi-
tional weight and began to gradually return to their starting weight.
Pair-fed group displayed a slightly larger weight-loss compared
to EX4-treated group, a similar effect was indicated by a previous
study where body weight loss was  measured during nine days of
peripheral EX4 treatment (Yang et al., 2014). Animals pair-fed to
EX4 treated rats lost a similar amount of weight to the EX4 treated
rats indicating that body-weight loss after EX4 is primarily due to
reduced calorie intake rather than increased energy expenditure.
Restriction of food intake to the amount voluntarily eaten by
EX4-treated rats resulted in a signiﬁcant increase in the expres-
sion of genes encoding 5-HTR1A (F(2,30) = 6.42, p < 0.005), 5-HTR2A
(F(2,30) = 8.26, p < 0.005), 5-HTR2C (F(2,30) = 10.45, p < 0.0005), and
5-HTR3A (F(2,30) = 12.53, p < 0.0001) but not Tph2 (F(2,30) = 1.83,
p = 0.18) in the amygdala (Fig. 6H). While EX4 treatment did not
change the expression of any genes measured when compared to
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Fig. 5. Dorsal raphe GLP-1R activation is sufﬁcient to increase anxiety-like behavior. GLP-1 or EX4 potently reduce the amount of time spent in the white chamber without
altering general motor activity in the black and white box (A-B). n = 9–15 per each treatment group. Also elevated plus maze data suggest increased anxiety-like behavior
since  the rats treated with EX4 or GLP-1 spent three times less time in the open arms of the maze compared to vehicle treated controls (C), they are also less likely to enter
the  open arm (D). However they do not display signs of malaise as measured in the PICA response (E). Notably the doses of agonists used did not produce a signiﬁcant effect
o  impo
g tion o
r
a
p
a
i
o
in  anxiety-like behavior when applied to the ventricle, indicating the raphe as an
roup. Data are expressed as mean ± SEM. Photomicrograph of a 40 m coronal sec
aphe  according to the rat brain atlas (F). *p < 0.05, **p  < 0.005.
d libitum-fed controls, it did alter gene expression compared to
air-fed rats (arguably a more appropriate control since it takes into
ccount the changes in the brain induced by reduced body weight
n EX4-treated rats). Thus, EX4 attenuated the increased expression
f serotonin receptor genes which was induced by restricted feed-
ng, as shown by the reduced expression compared to pair-fed rats.rtant neural substrate for the anxiety effect of GLP-1. n = 7–10 per each treatment
f rat brain illustrating the injection site and schematic representation of the dorsal
Serotonin turnover was not elevated after chronic EX4 treatment
(Fig. 6I).5. Discussion
Using three tests of anxiety-like behavior, we show that acute
peripheral or central GLP-1R activation is anxiogenic and identify
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Fig. 6. Chronic GLP-1R activation reduces depression-like behavior. In contrast to the acute effects of EX4, rats chronically treated with EX4 displayed reduced depression-like
behavior as evidenced by an increased amount of time spent on active behavior—swimming (A) and a reduced amount of time spent on passive behavior—immobility (B) in
the  forced swim test. Rats pair-fed to the amount of food eaten by EX4 rats did not show any signiﬁcant changes in behavior. Climbing behavior was not signiﬁcantly altered
by  any of the treatments (C). Chronic EX4 treatment or pair feeding did not change anxiety-like behavior (D-E). Rats chronically treated with EX4 reduced their body weight
(F).  The reduction in body weight was consistent with reduced chow intake in EX4 treated rats compared to the vehicle treated animals (G). Restriction of food intake to the
amount  voluntarily eaten by EX4-treated rats resulted in a signiﬁcant increase in the expression of genes encoding 5-HTR1A, 5-HTR2A, 5-HTR2C, and 5-HTR3A in the amygdala,
this  effect was attenuated by chronic EX4 treatment (H). Chronic EX4 treatment did not signiﬁcantly increase serotonin turnover in the amygdala (I). Data are expressed as
mean  ± SEM. n = 8–14 per each treatment group. *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005.
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he DR as a neural substrate for this effect. Increased anxiety can
esult from elevated serotonergic neurotransmission in the amyg-
ala; therefore serotonin turnover and gene expression of several
erotonergic receptors were analyzed in this area. Central acute
LP-1R activation resulted in increased serotonin turnover and
ncreased expression of several serotonin receptors in the amyg-
ala. In contrast to the acute effects of central GLP-1R activation,
hronic daily central treatment with the GLP-1 analog, EX4, did not
lter anxiety-like behavior but instead led to reduced depression-
ike behavior in the FST. Chronic GLP-1R activation, unlike the acute
reatment, did not increase serotonin turnover or serotonin recep-
or expression in the amygdala.
The presence of GLP-1R in the DR suggests a potential role
or GLP-1 in emotional processes (Merchenthaler et al., 1999).
erotonin-producing neurons are localized in the raphe nuclei,
hich send projections throughout the brain. Accordingly, the
mygdala receives serotonergic innervation from the DR nucleus
Vertes, 1991) while the hippocampus receives serotonergic inner-
ation from the median raphe (McQuade and Sharp, 1997).
uided by our results indicating an increased anxiety-like behav-
or after central GLP-1R agonist application and increased serotonin
urnover in the amygdala, but not the hippocampus, we hypothe-
ized that the anxiogenic effects of GLP-1 may  originate from direct
R GLP-1R activation. The results of the DR-directed GLP-1 and
X4 microinjections conﬁrm this idea and show that DR GLP-1R
ctivation alone is sufﬁcient to increase anxiety-like behavior. The
reproglucagon neurons situated in the hindbrain’s solitary tract
ay  be a primary source of the endogenous ligand to the raphe
s GLP-1-producing neurons from this area were recently shown
o innervate the brainstem raphe nuclei (Llewellyn-Smith et al.,
013).
While selective serotonin reuptake inhibitors (SSRIs) are used
o effectively treat a spectrum of anxiety disorders, some patients
ay  paradoxically experience an increase in anxiety during the ini-
ial stages of SSRI treatment, an effect that eventually subsides after
hronic treatment. Acute SSRI administration increases 5-HT con-
entrations in the amygdala and hippocampus (Bosker et al., 2001;
ervas et al., 2000) and can enhance amygdala activity in healthy
umans (Del-Ben et al., 2005; McKie et al., 2005) and exacerbate the
xpression of anxiety (Grillon et al., 2007). The early onset anxiety
hat subsides with chronic exposure and improvement of depres-
ion symptoms, but only after chronic exposure seen here with
LP-1R activation, resembles the action of the SSRIs. SSRIs, or other
gents that increase serotonin signaling, can elicit anxiety, both in
odents and humans, during the ﬁrst few days of treatment, and
eeks before anxiolytic and anti-depressant effects emerge (Nutt
t al., 1999; Pettersson et al., 2015; Sinclair et al., 2009; Wise et al.,
972).
5HT1AR is an autoreceptor in the DR, known to inhibit DR sero-
onin neurons (Asan et al., 2013). In the current study, however,
he expression of this receptor or the enzyme responsible for sero-
onin synthesis is not altered in the DR. In contrast, in the amygdala
cute EX4 injection increased the expression of several serotonin
eceptors (5HT2A and 5HT2C) in addition to increasing serotonin
urnover. The acute anxiogenic effect of SSRI may  involve 5HT2CRs
n the basolateral amygdala (Vicente and Zangrossi, 2012). Wealth
f evidence from both animal and clinical studies suggests an anx-
ogenic role of 5HT2C. Overexpression of 5HT2CR in limbic areas
esults in increased anxiety (Kimura et al., 2009), and conversely
HT2CR knock-out mice display reduced anxiety-like behavior
Heisler et al., 2007). Nevertheless amygdala serotonin receptor
xpression alone may  not be entirely predictive of increased anxi-
ty, as all serotonin receptors measured were strikingly increased
n the amygdala of rats pair-fed to EX4 rats, compared to their ad
ibitum-fed controls, yet the pair-fed rats did not show elevated
evels of anxiety or depression-like behavior. The lack of changesdocrinology 65 (2016) 54–66
in anxiety or depression by restricted feeding (pair fed to the EX4
group) is curious as it may  indicate that reduced intake or body
weight can be dissociated from the positive effects of EX4 on mood,
and also that reduced intake itself does not produce beneﬁcial or
negative changes in mood. It is also possible that the lack of anxiety
or depression-like behavior in pair-fed animals is due to the oppos-
ing effects of the different 5HTRs that were overexpressed in these
animals. While 5HT2AR and 5HT2CR are associated with increased
anxiety, 5HT3AR stimulation decreases anxiety behavior within the
amygdala (Bhatnagar et al., 2004; Harrell and Allan, 2003; Kelley
et al., 2003; Vicente and Zangrossi, 2012; Zangrossi and Graeff,
1994). Therefore increased expression of these receptors together
may  not lead to any behavioral differences regarding anxiety or
depression. Furthermore, chronic food restriction per se has previ-
ously been shown to increase depression and anxiety-like behavior
in rats as shown in FST and EPM (Jahng et al., 2007). However,
animals in the cited experiment were food restricted for a longer
period of time, therefore the effects on 5HT expression may  precede
an anxious phenotype, which may  have been present after further
food deprivation. In contrast, other studies have shown that caloric
restriction instead reduces anxiety and depression (Lutter et al.,
2008). This would indicate that the anorexic effects of EX4 may be
sufﬁcient to exert the anti-depression effects demonstrated in this
study. However, in the current study pair-fed animals did not dis-
play these same characteristics after chronic treatment indicating
that the effects on mood shown here are not due to food restriction
alone. In contrast to these acute effects of EX4 on amygdala sero-
tonin receptors, chronic treatment with EX4 did not change the
expression of any serotonin receptors measured when compared
to ad libitum fed rats, or potently reduce the expression of all sero-
tonin receptors measured when compared to the pair-fed control
group.
The serotonergic hypothesis of depression is still debated, espe-
cially considering the discrepancy between the immediate increase
in serotonin produced by SSRIs and a much delayed relief in depres-
sion symptoms along with the fact that nearly a third of patients do
not get symptom relief from SSRI treatment (Rossetti et al., 2014).
Anti-depression therapies have been suggested to increase neuro-
genesis (Anacker et al., 2011; Mendez-David et al., 2013; Santarelli
et al., 2003). Interestingly several lines of evidence suggest that EX4
is also neurotrophic and neuroprotective (Holscher, 2014; Li et al.,
2009). Thus, it is possible that the anti-depressant effect of GLP-
1R activation is linked to its action to reduce neurodegeneration
and increase neurogenesis, though this idea is still rather specu-
lative and requires further research. The divergent role of EX4 on
anxiety and depression-like behaviors is also reminiscent of one
previously observed with genetic overexpression of brain derived
neurotrophic factor (BDNF) (Govindarajan et al., 2006).
In addition to serotonin, the GLP-1 system has also been shown
to interact with dopamine (Anderberg et al., 2014; Egecioglu
et al., 2013; Richard et al., 2015; Sorensen et al., 2015). Dopamine
has been implicated in depression (Dunlop and Nemeroff, 2007).
Optogenetically-driven inhibition of VTA dopamine neurons has
been shown to induce depression-like behavior (Tye et al., 2013).
Furthermore this phenotype can be reversed by photoactivation
of VTA dopamine neurons projecting to the ventral striatum (Tye
et al., 2013). Interestingly, pretreatment with the GLP-1R agonist,
EX4, was  previously shown to attenuate striatal cocaine-induced
dopamine release in mice (Sorensen et al., 2015). In addition EX4
has also been shown to have an anti-psychotic-like effect after
pretreatment with the non-selective dopamine receptor agonist-
apomorphine (Dixit et al., 2013), and to decrease locomotor activity
induced by administration of amphetamine, a drug which acts
to increase central dopamine levels (Erreger et al., 2012). These
studies suggest the ability of EX4 to decrease central dopamine
levels; depression may  be associated with reduced dopaminergic
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ransmission, indicating that the effects of GLP-1 and its ago-
ists, shown here, are unlikely to be mediated through actions on
he dopaminergic pathway. However, all GLP-1 studies discussed
bove examined acute perturbations of the GLP-1 system, thus the
mpact of chronic manipulations, as done here, on the dopaminer-
ic striatal transmission remains unknown and could be of interest
or the role of the GLP-1 system in modulating depression-like
ehavior. The dopaminergic pathway has also been implicated in
nxiety-like behavior (Bananej et al., 2012; de la Mora et al., 2010,
012; Mohammadi et al., 2015). For instance apomorphine may
ave anxiolytic properties through its actions on the amygdala
Zarrindast et al., 2011). In addition D1 and D2 antagonists have
een shown to increase anxiety by acting in this area (Zarrindast
t al., 2011). Central acute GLP-1R activation has previously been
hown to elevate dopamine turnover in the amygdala and the
norexic effects of GLP-1 may  be partly mediated through actions
n D2 receptors within this area (Anderberg et al., 2014). As GLP-
 has been shown to elevate dopamine activity in the amygdala,
his would instead imply a reduction in anxiety-like behavior based
n previous literature, thus dopaminergic signaling, at least in the
mygdala, remains an unlikely candidate mediator of the acute
nxiogenic effect of GLP-1 or its analogs.
Our results are strengthened by the fact that treatment with the
ndogenous ligand, GLP-1, as well as the clinically utilized stable
nalog, EX4, resulted in elevated anxiety. Interestingly, however,
LP-2, another peptide produced from the same precursor gene
s GLP-1 (Tang-Christensen et al., 2000), did not increase anxiety.
n fact LV-injected GLP-2 tended to reduce anxiety-like behavior.
hus, central GLP-1 and GLP-2, despite the similarities in their pro-
uction and release, may  have different roles in the regulation of
nxiety. This may  be surprising as many of the central effects of
LP-1, for example reduction of food intake, body weight, gas-
rointestinal motility and regulation of blood glucose are, to some
xtent, mimicked by GLP-2 (Guan, 2014). However, this is not the
rst time these two co-secreted peptides were reported to have
ivergent effects, previous studies have shown that when released
n the intestine these peptides have opposing impact on intestinal
ipid packaging (Hein et al., 2013).
The current study, as well as several others (Gulec et al., 2010;
inzig et al., 2003; Moller et al., 2002), ﬁnds a clear anxiogenic
ffect of central acute GLP-1R stimulation. In contrast to the anx-
ogenic effects of acute GLP-1 and EX4 treatment reported here,
eripheral treatment with another GLP-1 agonist, liraglutide, or the
PP-IV inhibitor sitagliptin, was very recently shown to decrease
nxiety-like behavior measured in the EPM task (Sharma et al.,
015a,b,c). Similarly a whole-body knockout of the GLP-1R results
n either non-altered anxiety-like behavior or an increased anxiety-
ike behavior in the EPM test in mice (Harasta et al, 2015; MacLusky
t al., 2000). Though it is important to note that other parameters,
ike the body-weight of the null mice which is the same or even
ower than that of control mice, are inconsistent with the well doc-
mented role of GLP-1R in body weight regulation (MacLusky et al.,
000; Seeley et al., 2000). The divergent results in the earlier men-
ioned pharmacological studies compared to the current study can
e due to the different routes of drug administration (peripheral
s. central), different GLP-1 analogs/enhancers used (liraglutide or
itagliptin vs. EX4 or GLP-1), different rat strains (Wistar vs. Sprague
awley), or different testing time point in relation to drug injec-
ions (4 h vs. 20 min). While any of these differences could have
ontributed to the contrasting results, the strain differences could
ave been of particular importance since it was previously reported
hat Wistar Kyoto rats and Sprague Dawley rats have different FST
esponses at baseline but also, importantly, respond differently
o noradrenergic or serotonergic antidepressants in the FST test
Lopez-Rubalcava and Lucki, 2000). Furthermore of the four doses
ested only one dose of liraglutide or sitagliptin increased EPM opendocrinology 65 (2016) 54–66 63
arm entry, indicating that this effect may  not be robust (Sharma
et al., 2015a,b,c). In order to eliminate the route of administration
as a potential source of varied effect of GLP-1 analogs on anxiety-
like behavior, in the current study we  also tested the impact of
peripherally injected EX4 on anxiety-like behavior and found that
in line with our central-injection results, peripherally injected EX4
resulted in anxiety-like behavior in both the EPM and open ﬁeld
tests. An anxiolytic effect of chronic EX4 administration was also
indicated by another study, performed in diabetic mice (Komsuoglu
Celikyurt et al., 2014). These differences may  be due to different
species (mice vs. rats) or the disease state of the animals during
testing (streptozotocin-induced diabetic mice vs. healthy rats), the
latter idea is especially compelling since diabetes alone seems to
induce severe anxiety in the mice that is partially attenuated by
EX4 (Komsuoglu Celikyurt et al., 2014). Additionally, relieving dia-
betes alone, in other words improved glucoregulation produced by
peripheral treatment with EX4, may  be a major contributing factor
to the reduced anxiety in these mice. In addition, recently, another
group reported no effects on anxiety-like behavior measured in the
black and white test after acute or chronic subcutaneous adminis-
tration of the GLP-1 agonists EX4 or liraglutide in mice (Krass et al.,
2012, 2015).
In line with the results of the current central administration
focused study, three recent studies report a clear anti-depressive
impact of peripheral EX4 or liraglutide (Sharma et al., 2015a;
Isacson et al., 2011; Komsuoglu Celikyurt et al., 2014). Sharma and
colleagues show that chronic liraglutide treatment reverses depres-
sive behavior associated with long-term antipsychotic treatment in
female rats (Sharma et al., 2015a), providing additional evidence of
the potential anti-depressive effects of chronic GLP-1 agonist treat-
ment. They also show that in control rats four days of peripheral
liraglutide injections was sufﬁcient to reveal a reduced immobility
behavior in the FST test. In contrast to the differential effects on anx-
iety reported by Komsuoglu Celikyurt and colleagues (Komsuoglu
Celikyurt et al., 2014), compared to this study, a profound effect
of EX4 on anti-depressive behavior was  reported in the diabetes-
induced mice, further supporting our results of the anti-depressive
effects of EX4 and implicating that these effects may  be present both
in healthy and diabetic subjects. Similarly our results are in line
with another previous study in which peripherally administered
EX4 was  shown to decrease immobility in the FST after chronic,
but not acute treatment (Isacson et al., 2011). These studies collec-
tively also indicate that the antidepressant effects of GLP-1 agonist
treatment are present after peripheral administration, in addition
to central administration as in the current study, which implicates
that peripherally injected GLP-1 agonists can affect emotionality
behavior. Thus these effects may  also be present in patients receiv-
ing peripherally administered GLP-1 analogs. One recent study did
not ﬁnd any effects of 35-day peripheral treatment with either EX4
or liraglutide in rats or mice on FST (Krass et al., 2015). However
signiﬁcant methodological differences exist between this study and
all other studies discussed in this paragraph. Namely in the study
by Krass et al. (2015), rats received the pre-test 35 days before the
FST test, and, importantly, the FST test lasted 10 min  for rats and
6 min  for mice, and only behavior from the last 6 min  for rats and
last 4 min  of the test for mice was analyzed. Finally, in (Krass et al.,
2015) both rats and mice were also subjected to an open-ﬁeld test
immediately before the FST test. These differences are substantial
and may  have contributed to the lack of effect in the study by Krass
and colleagues.
Acute GLP-1R stimulation led to increased anxiety-like behav-
ior while chronic stimulation of these receptors led to reduced
depression-like behavior. It is possible that the differential effects
displayed after chronic treatment with the agonist may  indicate
potential desensitization at the central GLP-1R, however previous
studies administering GLP-1 or its analogs chronically demon-
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trated potent effects of GLP-1, with respect to body weight, food
ntake and glucose homeostasis throughout a 7 or 14 day treat-
ent period (Baggio et al., 2004; Davis et al., 1998). Desensitization
tudies conducted in cells have previously shown a concentration-
ependent decrease in speciﬁc binding of the GLP-1R; however
his did not result in functional desensitization (Davis et al., 1998).
n addition in vivo studies did not indicate the presence of recep-
or desensitization after chronic GLP-1R stimulation regarding its
ffects on food intake (Davis et al., 1998) supporting the idea that
he effects on mood in this study are not due to differences in
eceptor sensitivity caused by chronic stimulation.
The higher prevalence of depression and other mood disorders
n obese patients and negative effects on mood of previously avail-
ble anti-obesity treatments highlight the need for experimental
tudies on the impact on mood of newly emerging obesity treat-
ents. Here we show that GLP-1R activation, a recently approved
nti-obesity treatment, induces anxiety immediately after the com-
encement of the treatment, this anxiety subsides with chronic
reatment and is in fact replaced by positive effects on mood mani-
ested by reduced depression-like behavior. These results may  have
irect relevance to the clinic, and indicate that EX4 may  be espe-
ially useful for those obese patients manifesting with comorbid
epression. They also may  warrant vigilance on the part of treating
hysicians during the initial phase of the treatment where, similarly
o what has been previously observed with SSRIs, an elevation in
nxiety behavior may  be observed.
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